Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 20;92(4):263-277.
doi: 10.3390/arm92040026.

Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies

Affiliations
Review

Cystic Fibrosis: Understanding Cystic Fibrosis Transmembrane Regulator Mutation Classification and Modulator Therapies

Saba Anwar et al. Adv Respir Med. .

Abstract

A common life-threatening hereditary disease, Cystic Fibrosis (CF), affects primarily Caucasian infants. High sweat-salt levels are observed as a result of a single autosomal mutation in chromosome 7 that affects the critical function of the cystic fibrosis transmembrane regulator (CFTR). For establishing tailored treatment strategies, it is important to understand the broad range of CFTR mutations and their impacts on disease pathophysiology. This study thoroughly investigates the six main classes of classification of CFTR mutations based on their functional effects. Each class is distinguished by distinct molecular flaws, such as poor protein synthesis, misfolding, gating defects, conduction defects, and decreased CFTR expression at the apical membrane. Furthermore, this paper focuses on the emerging field of CFTR modulators, which intend to restore CFTR function or mitigate its consequences. These modulators, which are characterized by the mode of action and targeted mutation class, have the potential to provide personalized therapy regimens in CF patients. This review provides valuable insights into the genetic basis of CF pathology, and highlights the potential for precision medicine methods in CF therapy by thoroughly investigating CFTR mutation classification and related modulators.

Keywords: cystic fibrosis; fibrosis transmembrane regulator; modulators; pathophysiology; targeted mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of CFTR.
Figure 2
Figure 2
ΔF508 in CFTR.

References

    1. Rohlfs E.M., Zhou Z., Heim R.A., Nagan N., Rosenblum L.S., Flynn K., Scholl T., Akmaev V.R., Sirko-Osadsa D.A., Allitto B.A. Cystic fibrosis carrier testing in an ethnically diverse US population. Clin. Chem. 2011;57:841–848. doi: 10.1373/clinchem.2010.159285. - DOI - PubMed
    1. Fanen P., Wohlhuter-Haddad A., Hinzpeter A. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int. J. Biochem. Cell Biol. 2014;52:94–102. doi: 10.1016/j.biocel.2014.02.023. - DOI - PubMed
    1. Ong T., Ramsey B.W. Cystic fibrosis: A review. JAMA. 2023;329:1859–1871. doi: 10.1001/jama.2023.8120. - DOI - PubMed
    1. De Boeck K., Amaral M.D. Progress in therapies for cystic fibrosis. Lancet Respir. Med. 2016;4:662–674. doi: 10.1016/S2213-2600(16)00023-0. - DOI - PubMed
    1. Sheema, Bashir K., Fiaz S., Khan A.W., Haqqani S., Bibi A., Nawaz K., Khan M.A., Ullah A. Molecular identification of HCV genotypes among injecting drug users having HCV and HIV co-infection. Bull. Biol. Allied Sci. Res. 2024;2024:71. doi: 10.54112/bbasr.v2024i1.71. - DOI

MeSH terms

Substances

LinkOut - more resources